论文部分内容阅读
Objective.: To observe the effect and security of the combination therapy of sorafenib and radiofrequency ablation (RFA) for advanced HCC.Methods: Twenty-four advanced HCC patients treated with sorafenib for more than 3 months were divided into two groups:sorafenib alone (13 cases) and RFA/sorafenib (11 cases).The tumor status of these patients was evaluated with computed tomography (CT) every 1 to 2 months.The progression-free survival (PFS), overall survival (OS), and adverse effects of the treatment were investigated.